MedMira Inc. MIR

Updated: 10 Sep 2026

TSX-V | Biotech | Rapid diagnostics and biotechnology

No signal published yet

We already track MedMira and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow MedMira free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
TSX-V
Type
Biotech
Sector
Rapid diagnostics and biotechnology
We're already tracking MedMira Inc. — here are the latest events we've registered

Recent News

  • On June 29, 2026, MedMira reported its third-quarter financial results for fiscal year 2026, generating revenues of CAD 241,189. The company highlighted regulatory progress in Canada for its Multiplo TP/nTP syphilis antibody test as well as new regulatory initiatives in Australia and the EMEA region.

What Firelda Watch includes for MedMira Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of MedMira Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow MedMira Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow MedMira free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

MedMira Inc. MIR
MedMira — follow and we'll monitor it
Follow MedMira free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.